Be the first to like this
Market research analysts at Technavio predict that the global clostridium difficile treatment market will grow steadily at a CAGR of over 5% by 2021. This market research analysis identifies the development of novel therapies as one of the primary growth factors for this market. The clostridium difficile infection (CDI) is a leading cause of infectious diarrhea, globally. The recurrence of CDI causes a significant economic burden on the healthcare systems of countries due to a lack of assured outcomes, thereby increasing demand for novel CDI therapies. To address these needs vendors are conducting R&D to develop novel treatments for CDI. For instance, ridinilazole is a novel small molecule antibacterial that is administered orally. It is currently in Phase III of its development cycle. The drug has demonstrated high efficacy during Phase II and is expected to do the same during Phase I. Positive results from Phase III clinical trials can establish the molecule as a differentiated therapy for the treatment of CDI.
The emergence of vaccines is one of the latest trends that will gain traction in the clostridium difficile treatment market in the coming years. The increasing incidence of CDI has encouraged vendors to develop vaccines that prevent CDI and provide long-term protection against it. Additionally, there are several vaccines for CDI that are in various phases of development that are designed to prevent CDI and are cost-effective.